海思科(002653.SZ)子公司獲得《藥品GMP證書》
格隆匯12月4日丨海思科(002653.SZ)公佈,公司全資子公司遼寧海思科製藥有限公司(“遼寧海思科”)於近日收到遼寧省藥品監督管理局頒發的中華人民共和國《藥品GMP證書》。
按照國家食品藥品監督管理局《藥品生產質量管理規範認證管理辦法》的規定,經審查,遼寧海思科的大容量注射劑(含多層共擠輸液袋)(601車間)符合中華人民共和國《藥品生產質量管理規範》要求,特發《藥品GMP證書》,有效期至:2024年11月28日。
此次獲得《藥品GMP證書》,標誌着遼寧海思科位於瀋陽的生產基地可以正式生產和銷售複方氨基酸注射液(18AA-VII),緩解原生產地址產能不足問題,將對公司未來生產經營產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.